TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS, INC. (TENX): 6 pipeline candidates · 4 upcoming catalysts · ~39 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
38.7 months
D/E 0.07 · 86% dilution
Lead: Phase 3
6 candidates
4 upcoming, next in ~836d
N/A
A transparent, data-derived signal for TENAX THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$314.9M
Cash
$118.8M
Quarterly Burn
$9.3M
Runway
38.7 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in TENAX THERAPEUTICS, INC.'s pipeline?
TENAX THERAPEUTICS, INC. (TENX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TENAX THERAPEUTICS, INC.'s lead drug candidate?
TENAX THERAPEUTICS, INC.'s most advanced tracked candidate is imatinib (Preclinical) for pulmonary arterial hypertension ("PAH").
What is TENAX THERAPEUTICS, INC.'s next catalyst?
TENAX THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens" — expected October 1, 2028.
What is TENAX THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TENAX THERAPEUTICS, INC. has approximately 38.7 months of cash runway.
What is TENAX THERAPEUTICS, INC.'s market capitalization?
TENAX THERAPEUTICS, INC.'s market capitalization is approximately $314.9M.
Get the full picture on TENAX THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.